Last reviewed · How we verify
BMS-986374
BMS-986374 is a selective inhibitor of protein arginine methyltransferase 5 (PRMT5) that blocks symmetric dimethylarginine formation on target proteins.
BMS-986374 is a selective inhibitor of protein arginine methyltransferase 5 (PRMT5) that blocks symmetric dimethylarginine formation on target proteins. Used for Metastatic non-small cell lung cancer (NSCLC) with MTAP deletion, Other solid tumors with MTAP loss or PRMT5 dependency.
At a glance
| Generic name | BMS-986374 |
|---|---|
| Also known as | Ozanimod |
| Sponsor | Bristol-Myers Squibb |
| Drug class | PRMT5 inhibitor |
| Target | PRMT5 (Protein Arginine Methyltransferase 5) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
PRMT5 is an epigenetic enzyme that catalyzes the addition of methyl groups to arginine residues on histone and non-histone proteins, regulating gene expression and protein function. By inhibiting PRMT5, BMS-986374 disrupts methylation-dependent pathways involved in cancer cell survival and proliferation, particularly in tumors with certain genetic dependencies. This mechanism is especially relevant in cancers with MTAP loss or other genetic alterations that create synthetic lethal interactions with PRMT5 inhibition.
Approved indications
- Metastatic non-small cell lung cancer (NSCLC) with MTAP deletion
- Other solid tumors with MTAP loss or PRMT5 dependency
Common side effects
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice (PHASE4)
- A Lactation Study in Women Receiving Treatment With Ozanimod (PHASE4)
- A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy (PHASE2, PHASE3)
- A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis (PHASE4)
- A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS-986374 CI brief — competitive landscape report
- BMS-986374 updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI